The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

Jarome and his team found that aging disrupts K63 polyubiquitination in two distinct areas of the brain. In the hippocampus, ...

Scientists from Oxford's Radcliffe Department of Medicine have achieved the most detailed view yet of how DNA folds and ...